Peijia Medical Ltd
| Preis (2026-07-24) | 52W Hoch | 52W Tief |
| 4.22 HKD | 9,36 HKD | 3,73 HKD |
| Analysten Konsens | Buy | Outperform | Hold | Underperform | Sell |
| - HKD | - | - | - | - | - |
| #Shares | Short [%] | Short Ratio |
| 669.511.953 | - | - |
Beschreibung
(automatisch übersetzt)
Peijia Medical Limited, together with its subsidiaries, engages in the research, development, manufacturing, and sales of transcatheter valve therapeutic and neurointerventional procedural medical devices in the People's Republic of China. It operates through Transcatheter Valve Therapeutic Business, Neurointerventional Business, and Future Technology Business segments. The company's products include transcatheter aortic valve replacement (TAVR) systems, crosslinked dry-tissue and polymeric tri leaflet TAVR systems, transcatheter aortic valve systems, lithotripsy valvuloplasty technology and interventional robotics technology, transseptal mitral valve replacement systems, transfemoral balloon catheter, introducer sheath, pre-shaped guidewire, detachable coils, balloon guide catheter, aspiration catheter, stent retriever, delivery balloon dilatation catheter, balloon dilatation catheter, microcatheter, micro guidewire, micro guidewire, guide catheter, distal access guide catheter, intermediate catheter, and power supply. In addition, it engages in the trading and holding business. Peijia Medical Limited was incorporated in 2012 and is headquartered in Suzhou, the People's Republic of China.
| Allgemein | Profitabilität | ||
|---|---|---|---|
| Industriesektor ? | Gesundheitsprodukte | Operative Marge [%] ? | - |
| Marktkapitalisierung ? | - HKD | ROIC [%] ? | - |
| Enterprise Value ? | - HKD | ROIC/WACC ? | - |
| Bewertung | |||
| KGV [TTM] ? | - | EV/FCFF [TTM] ? | - |
| KGV [Forward] ? | - | EV/Sales [TTM] ? | - |
| KUV [TTM] ? | - | EV/EBITDA [TTM] ? | - |
| KBV [TTM] ? | - | ||
| Finanzielle Risiken und Liquidität | |||
| Künstl. Bonität ? | - | Zinsdeckungsgrad ? | - |
| Verschuldungsgrad [Buch] ? | - | Cash Ratio - L1 ? | - |
| Verschuldungsgrad [Markt] ? | - | Quick Ratio - L2 ? | - |
| Current Ratio - L3 ? | - | ||
| Dividenden und Aktienrückkäufe | |||
| Vergangene Jahresdividende ? | - HKD | Ausschüttungsquote ? | - % |
| Erwartete Jahresdividende ? | - HKD | Erwartete Dividendenrendite ? | - % |
| Netto Aktienrückkäufe [TTM] ? | - CNY | Effektive Ausschüttungsquote ? | - % |
| Dividendenauszahlung [TTM] ? | - CNY | Effektive Auszahlungsrendite ? | - % |
| Netto Gesamtauszahlung [TTM] ? | - CNY | ||
Kennzahlen
Gewinn/Verlust
Cash Flow
Dividenden & Aktienrückkäufe
Bilanz
Vergleichbare Unternehmen
| Name | Takani Score ? | Marktkapitalisierung | Industriesektor | Land/Region | KGV TTM | Forward KGV ? | |
|---|---|---|---|---|---|---|---|
| Beijing Chunlizhengda Medical Instruments Co Ltd | 60,55 | 421.996.913,28 USD | Gesundheitsprodukte | China | 10.56 | - | |
| Microport Cardioflow Medtech Corp | 32,41 | 170.426.675,52 USD | Gesundheitsprodukte | China | - | 312.5 | |
| AK Medical Holdings Ltd | 77 | 741.772.723,2 USD | Gesundheitsprodukte | China | 15.51 | 17.54 | |
| New Horizon Health Ltd | 17,38 | 808.971.302,4 USD | Gesundheitsprodukte | China | - | - | |
![]() | LifeTech Scientific Corp | 35,64 | 824.813.844,48 USD | Gesundheitsprodukte | China | 36.75 | - |
![]() | MicroPort Scientific Corp | 26,49 | 1.599.845.552,64 USD | Gesundheitsprodukte | China | - | 526.32 |
| Venus Medtech Hangzhou Inc | 9,73 | 62.976.436,08 USD | Gesundheitsprodukte | China | - | 35.21 | |
| Shanghai MicroPort MedBot Group Co Ltd | 21,72 | 2.658.820.976,64 USD | Gesundheitsprodukte | China | - | - | |
| Ningbo David Medical Device Co Ltd | 39,55 | 387.680.256 USD | Gesundheitsprodukte | China | 35.08 | - | |
| Zhejiang Orient Gene Biotech Co Ltd | 11,36 | 531.742.616,986 USD | Gesundheitsprodukte | China | - | - |

